Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Accenture
Julphar
Merck
Citi
QuintilesIMS
US Department of Justice
Mallinckrodt
Argus Health

Generated: January 23, 2018

DrugPatentWatch Database Preview

Allergan Company Profile

« Back to Dashboard

Summary for Allergan
International Patents:816
US Patents:123
Tradenames:86
Ingredients:64
NDAs:101

Drugs and US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Sales Llc ACTIGALL ursodiol CAPSULE;ORAL 019594-002 Dec 31, 1987 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan PROPINE dipivefrin hydrochloride SOLUTION/DROPS;OPHTHALMIC 018239-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-010 Jul 9, 2012 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-004 Mar 9, 2001 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-002 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Allergan ACULAR LS ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 021528-001 May 30, 2003 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 020715-001 Jun 15, 2000 ➤ Subscribe ➤ Subscribe
Allergan BETAGAN levobunolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 019219-002 Dec 19, 1985 ➤ Subscribe ➤ Subscribe
Allergan Inc ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-004 Apr 5, 2002 ➤ Subscribe ➤ Subscribe
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021262-001 Mar 16, 2001 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 7.5% ➤ Subscribe 2/13/2017
➤ Subscribe Ophthalmic Solution 0.25% ➤ Subscribe 7/30/2014
➤ Subscribe Gel 10% ➤ Subscribe 6/19/2014
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 1/14/2013
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 10/9/2012
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 8/24/2011
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 8/23/2011
➤ Subscribe Ophthalmic Solution 0.01% ➤ Subscribe 4/5/2011
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 12/7/2010
➤ Subscribe Topical Solution 0.03% ➤ Subscribe 5/3/2010
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 3/2/2009
➤ Subscribe Ophthalmic Solution 0.03% ➤ Subscribe 12/22/2008
➤ Subscribe Ophthalmic Solution 0.2%/0.5% ➤ Subscribe 11/21/2008
➤ Subscribe Ophthalmic Solution 0.05% ➤ Subscribe 10/14/2008
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 8/19/2008
➤ Subscribe Ophthalmic Solution 0.30% ➤ Subscribe 7/19/2007
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 12/20/2006
➤ Subscribe Ophthalmic Solution 0.15% ➤ Subscribe 11/3/2006
➤ Subscribe Ophthalmic Solution 0.40% ➤ Subscribe 1/28/2005
Premature patent expirations for ALLERGAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Allergan

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,859,604 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid ➤ Subscribe
7,625,582 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor ➤ Subscribe
6,635,675 Method of treating chronic fatigue syndrome ➤ Subscribe
7,388,029 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins ➤ Subscribe
8,618,064 Methods of providing therapeutic effects using cyclosporin components ➤ Subscribe
8,318,070 Ocular implant made by a double extrusion process ➤ Subscribe
7,470,433 Formulations for transdermal or transmucosal application ➤ Subscribe
8,778,381 Ocular implant made by a double extrusion process ➤ Subscribe
8,048,445 Ocular implant made by a double extrusion process ➤ Subscribe
7,387,788 Pharmaceutical compositions of nicotine and methods of use thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Allergan Drugs

Supplementary Protection Certificates for Allergan Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/014 United Kingdom ➤ Subscribe PRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018
2015 00072 Denmark ➤ Subscribe PRODUCT NAME: OKULAER SKYLLEVAESKE OMFATTENDE PHENYLEPHRIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER HYDROCHLORID OG KETOROLAC ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER KETOROLACTROMETAMOL; REG. NO/DATE: EU/1/15/1018 20150730
2013 00053 Denmark ➤ Subscribe PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
/2004 Austria ➤ Subscribe PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
462 Luxembourg ➤ Subscribe PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
2016 00016 Denmark ➤ Subscribe PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
C0090 France ➤ Subscribe PRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728
/2001 Austria ➤ Subscribe PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
C0033 France ➤ Subscribe PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
2009 Austria ➤ Subscribe PRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Deloitte
US Army
Mallinckrodt
Harvard Business School
Covington
Citi
McKinsey
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot